David Schenkein is GV's latest general partner and will focus on life sciences while retaining a chairman position at oncology therapy developer Agios Pharmaceuticals.
David Schenkein, former chief executive of biopharmaceutical company Agios Pharmaceuticals, has been hired by GV, a corporate venturing subsidiary of internet technology conglomerate Alphabet, as a general partner.
Schenkein had joined Agios in 2009, and helped transform the company from a preclinical-stage startup to a business with two US-approved cancer drugs in the market. He announced his plans to step down from the CEO role in September 2018, though he will remain chairman.
Prior to joining Agios, Schenkein was the senior vice-president…
